Nanosonics Ltd (ASX: NAN) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Nanosonics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.02 billion
P/E Ratio 88.81
Dividend Yield 0.00%
Shares Outstanding 303.00 million
Earnings per share 0.042
Dividend per share N/A
Year To Date Return -18.86%
Earnings Yield 1.13%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Nanosonics Ltd (ASX: NAN)
    Latest News

    a woman
    Growth Shares

    Where to invest $10,000 in ASX 200 shares right now

    ResMed Inc. (ASX:RMD) and these ASX 200 shares could be great options for a $10,000 investment after the market volatility...

    Read more »

    a woman
    Coronavirus News

    3 of the best ASX 200 healthcare shares to buy right now

    Here's a closer look at 3 S&P/ASX 200 Index (ASX: XJO) healthcare shares to buy amidst the coronavirus pandemic.

    Read more »

    a woman
    Share Market News

    Leading brokers name 3 ASX 200 shares to buy today

    Leading brokers have named Webjet Limited (ASX:WEB) and these ASX 200 shares as buys this week. Here's why...

    Read more »

    a woman
    Share Fallers

    Why IDP Education, Kathmandu, Nanosonics, & SkyCity are tumbling lower

    IDP Education Ltd (ASX:IEL) and Nanosonics Ltd. (ASX:NAN) shares are two of four tumbling notably lower on the ASX on…

    Read more »

    a woman
    Coronavirus News

    Nanosonics share price on watch after coronavirus update

    The Nanosonics Ltd (ASX: NAN) share price is on watch this morning after the company announced a business update in…

    Read more »

    a woman
    How to invest

    Where to invest $1,000 into ASX shares in April

    Nanosonics Ltd (ASX:NAN) and these top ASX shares could be great places to invest $1,000 in April. Here's why I like…

    Read more »

    a woman
    Growth Shares

    The ASX 200 shares to buy when the bear market ends

    Here's why a2 Milk Company Ltd (ASX:A2M) and these ASX 200 shares could be the ones to buy when the bear…

    Read more »

    a woman
    Share Market News

    Top brokers name 3 ASX shares to buy for strong returns

    National Australia Bank Ltd (ASX:NAB) shares are one of three that top brokers have named as buys this week. Here's…

    Read more »

    a woman
    Share Market News

    3 ASX shares to buy when the bear market ends

    Altium Limited (ASX:ALU) and these ASX shares could be great ones to own when the bear market ends... and it will…

    Read more »

    a woman
    ⏸️ ASX Shares

    10 top ASX shares to buy after the coronavirus crash

    Afterpay Ltd (ASX:APT) and CSL Limited (ASX:CSL) are 2 of 10 ASX shares that could be great options after the coronavirus crash...

    Read more »

    a woman
    Share Market News

    Where I'd invest $1,000 into ASX shares after the market crash

    The market crash is providing plenty of investments opportunities. Here's why I'd invest $1,000 into a2 Milk Company Ltd (ASX: A2M)…

    Read more »

    a woman
    Share Market News

    MoneyMe, Nanosonics and Data#3 shares soar higher today

    As the S&P/ASX 200 (INDEXASX: XJO) dropped lower again today, here are 3 ASX shares that bucked the trend and…

    Read more »

    Frequently Asked Questions

    No, Nanosonics Ltd does not pay dividends at this stage.

    Nanosonics Ltd listed on the ASX on 17 May 2007.

    NAN ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Nanosonics Ltd

    Nanosonics Ltd (ASX: NAN) is an Australian healthcare company specialising in infection prevention.

    The company has developed and commercialised an automated disinfection technology, the trophon device. Nanosonics says it represents the first major innovation in high-level disinfection for ultrasound probes in more than two decades and is fast becoming the global standard of care for ultrasound probe disinfection. The company also manufactures and distributes other related technologies.

    Nanosonics is based in Sydney with sales offices in the US and Europe.

    NAN Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    15 Nov 2024 $3.37 $0.02 0.60% 291,543 $3.36 $3.39 $3.31
    14 Nov 2024 $3.35 $0.05 1.52% 326,762 $3.30 $3.36 $3.29
    13 Nov 2024 $3.30 $-0.02 -0.60% 362,449 $3.31 $3.31 $3.21
    12 Nov 2024 $3.32 $0.04 1.22% 398,938 $3.30 $3.32 $3.21
    11 Nov 2024 $3.28 $0.03 0.92% 206,482 $3.26 $3.34 $3.24
    08 Nov 2024 $3.25 $0.01 0.31% 184,982 $3.20 $3.28 $3.18
    07 Nov 2024 $3.24 $0.04 1.25% 188,402 $3.20 $3.24 $3.18
    06 Nov 2024 $3.20 $0.03 0.95% 239,506 $3.21 $3.23 $3.12
    05 Nov 2024 $3.17 $0.01 0.32% 152,176 $3.11 $3.19 $3.11
    04 Nov 2024 $3.16 $-0.04 -1.25% 280,089 $3.21 $3.22 $3.14
    01 Nov 2024 $3.20 $0.00 0.00% 290,578 $3.15 $3.22 $3.12
    31 Oct 2024 $3.20 $-0.02 -0.62% 292,896 $3.17 $3.22 $3.17
    30 Oct 2024 $3.22 $-0.03 -0.92% 371,397 $3.25 $3.27 $3.18
    29 Oct 2024 $3.25 $-0.06 -1.81% 662,798 $3.32 $3.36 $3.20
    28 Oct 2024 $3.31 $-0.02 -0.60% 472,711 $3.30 $3.38 $3.26
    25 Oct 2024 $3.33 $0.02 0.60% 265,633 $3.36 $3.36 $3.30
    24 Oct 2024 $3.31 $-0.05 -1.49% 280,421 $3.35 $3.36 $3.30
    23 Oct 2024 $3.36 $-0.07 -2.04% 229,775 $3.41 $3.44 $3.34
    22 Oct 2024 $3.43 $-0.11 -3.11% 340,360 $3.51 $3.51 $3.40
    21 Oct 2024 $3.54 $0.02 0.57% 383,365 $3.51 $3.55 $3.49
    18 Oct 2024 $3.52 $-0.11 -3.03% 365,823 $3.58 $3.62 $3.52
    17 Oct 2024 $3.63 $0.04 1.11% 491,839 $3.59 $3.66 $3.57

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    01 Oct 2024 Michael Kavanagh Exercise 286,885 $1,058,605
    Exercise of options.
    01 Oct 2024 Michael Kavanagh Exercise 72,781 $268,561
    Conversion of securities.
    01 Oct 2024 Michael Kavanagh Issued 9,446 $34,855
    Exercise of options.
    01 Oct 2024 Michael Kavanagh Expiry 256,494 $946,462
    As advised by the company. Lapsed
    01 Oct 2024 Michael Kavanagh Issued 72,781 $268,561
    Conversion of securities.
    12 Sep 2024 Larry Marshall Buy 20,000 $71,873
    On-market trade.
    07 Jun 2024 David Fisher Sell 100,000 $303,769
    On-market trade.
    06 Jun 2024 Michael Kavanagh Sell 90,000 $274,151
    On-market trade.
    22 Mar 2024 Marie McDonald Buy 18,606 $49,999
    On-market trade.
    01 Mar 2024 Larry Marshall Buy 25,000 $68,182
    On-market trade.
    29 Feb 2024 Michael Kavanagh Issued 385,140 $1,051,432
    Issue of securities. 14,06,324 Rights
    28 Feb 2024 Steven Sargent Buy 36,460 $99,742
    On-market trade.
    16 Feb 2024 Michael Kavanagh Issued 44,054 $131,280
    Issue of securities. 10,21,184 Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Lisa Margaret McIntyre Non-Executive Director Dec 2019
    Dr McIntyre executive background is in strategy, particularly in the areas of medical technology and healthcare, with many years as a partner at L.E.K. Consulting in the US and Australia, where she led the Asia Pacific Health practice. She is also member of the Risk committee and Chair of Innovation and Development Committee.
    Dr Larry Marshall Non-Executive Director Oct 2023
    Dr Marshall is a technology innovator, physicist, and business leader. During his 26 years in the United States, Dr Marshall co-founded six companies in a range of markets including medical device which went public. Over the past 30 years, he has served as CEO/MD of six companies, and Chairman of four. He was MD, then co-Chairman of Arasor which he took public in 2006. He is also member of the Innovation and Development Committee.
    Mr Michael Kavanagh Chief Executive OfficerManaging Director Jul 2012
    Mr Kavanagh has more than 29 years of international commercial experience in the healthcare market, having held local, regional and global roles in medical device and pharmaceutical industries. Before joining Nanosonics, he was Senior Vice President of Global Marketing for the medical device company Cochlear Ltd, a position he held for more than 10 years.
    Ms Marie Elizabeth McDonald Non-Executive Director Oct 2016
    Ms McDonald has background in corporate and commercial law, having practised for many years as a partner at Ashurst. Ms McDonald was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia (2012 to 2013) and was a member of the Australian Takeovers Panel from 2001 to 2010. She is also member of the Innovation and Development Committee.
    Mr Steven Andrew Sargent Non-Executive DirectorNon-Executive Chairman Jul 2016
    Mr Sargent's career included 22 years at General Electric, where he gained multi-industry, international experience leading businesses in industries including healthcare, energy and financial services across the USA, Europe and Asia Pacific. Mr Sargent has been a Non-Executive Director of Origin Energy Limited and is also a Non-Executive Director of Ramsay Healthcare Limited (since December 2021). He is also member of the Risk and Innovation and Development Committee.
    Dr Tracey Leigh Batten Non-Executive Director Sep 2023
    Dr Batten brings over 30 years of experience in the healthcare sector gained in non-executive and executive roles, and medical practitioner and clinical roles. Dr Batten was CEO of Imperial College Healthcare NHS Trust in the UK, St Vincent's Health Australia, Eastern Health and Dental Health Services Victoria. She is also member of the Risk Committee and Innovation and Development Committee.
    Mr Matthew Carbines General CounselCompany Secretary May 2023
    -
    Jason Burriss Chief Financial Officer
    -
    Sunny Pillai Chief Information Officer
    -
    Matthew Lipscombe Chief Marketing Officer
    -
    Rod Lopez Chief Operating Officer (COO) and Regional President APAC
    -
    David Morris Chief Strategy Officer (CSO) and Regional President APAC
    -
    Steven Farrugia Chief Technology Officer
    -
    Matthew Carbines General CounselCompany Secretary
    -
    Ronan Wright Regional President for Europe & Middle East
    -
    Ken Shaw Regional President for the United States Canada and Latin America
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 51,277,573 16.92%
    Citicorp Nominees Pty Limited 50,339,477 16.61%
    J P Morgan Nominees Australia Pty Limited 39,860,096 13.16%
    BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 14,993,564 4.95%
    BNP Paribas Noms Pty Ltd 14,088,824 4.65%
    National Nominees Limited 12,429,010 4.10%
    UBS Nominees Pty Ltd 12,018,963 3.97%
    Mr Maurie Stang 8,429,534 2.78%
    Mr Bernard Stang 6,862,564 2.26%
    Mr Steve Kritzler 6,489,737 2.14%
    Australian Foundation Investment Company Limited 5,715,556 1.89%
    Mirrabooka Investments Limited 2,840,511 0.94%
    HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 2,534,549 0.84%
    Dr Harry Hirschowitz 2,139,090 0.71%
    BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 1,697,770 0.56%
    First Samuel Ltd Acn 086243567 <Anf Its Mda Clients A/C> 1,373,622 0.45%
    Certane Ct Pty Ltd <Nanosonics Eet A/C> 1,206,695 0.40%
    Citicorp Nominees Pty Limited <143212 Nmmt Ltd A/C> 1,054,295 0.35%
    Powerwrap Limited <Escala Sma Trading A/C> 919,357 0.30%
    Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> 908,378 0.29%

    Profile

    since

    Note